[{"orgOrder":0,"company":"Philip Morris International","sponsor":"Philip Morris International","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Philip Morris International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Philip Morris International \/ Philip Morris","highestDevelopmentStatusID":"1","companyTruncated":"Philip Morris International \/ Philip Morris"},{"orgOrder":0,"company":"Philip Morris International","sponsor":"Fertin Pharma AS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Philip Morris International","amount2":0.81999999999999995,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0.81999999999999995,"dosageForm":"Gum, Chewing","sponsorNew":"Philip Morris International \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"Philip Morris International \/ Philip Morris International"},{"orgOrder":0,"company":"Philip Morris International","sponsor":"Fertin Pharma AS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Philip Morris International","amount2":0.81999999999999995,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0.81999999999999995,"dosageForm":"Gum, Chewing","sponsorNew":"Philip Morris International \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"Philip Morris International \/ Philip Morris International"}]

Find Clinical Drug Pipeline Developments & Deals by Philip Morris International

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 15, 2021

                          Lead Product(s) : Nicotine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Recipient : Fertin Pharma AS

                          Deal Size : $820.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : OtiTopic develops the Asprihale patented dry powder inhalation ASA treatment to treat acute myocardial infarction as a self-administered aerosol. The company expects to move from clinical trials of Asprihale to filing for FDA approval at some point in 20...

                          Brand Name : Asprihale

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 09, 2021

                          Lead Product(s) : Aspirin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Recipient : OtiTopic

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 01, 2021

                          Lead Product(s) : Nicotine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Recipient : Fertin Pharma AS

                          Deal Size : $820.0 million

                          Deal Type : Acquisition

                          blank